Overview

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA

Status:
Terminated

Trial end date:
2019-10-03

Target enrollment:

Participant gender:

Summary

A study to assess effectiveness and safety of a drug FP-1201-lyo (Recombinant Human Interferon Beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic Aneurysm

Phase:

Phase 2

Details

Lead Sponsor:

Faron Pharmaceuticals Ltd

Treatments:

Interferon beta-1a
Interferon-beta
Interferons